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Background. We aimed to determine the optimal thallium-201-chloride (thallium-
201) dose using a novel ultrafast cardiac gamma camera with cadmium-zinc-telluride 
(CZT) solid-state semiconductor detectors (D-SPECT).  
Methods and Results. The optimal thallium-201 dose for obtaining left ventricular 
(LV) myocardial counts was determined from a phantom study. Consecutive 292 
patients underwent stress myocardial perfusion imaging with a thallium-201 injection. 
Stress test comprised exercise or pharmacological (adenosine) provocation. We 
calculated an optimal thallium-201 dose that resulted in better LV myocardial counts 
during 6 minutes of acquisition time. We corrected the respective values according to 
the patient’s age, sex, body mass index (BMI), and type of stress test. The lowest 
thallium-201 dose for obtaining acceptable imaging was 1.2 million counts. 
Radiopharmaceutical doses showed a positive correlation with the patient’s age (P 
< .001), sex (P = .012), BMI (P < .001), and type of stress test (P < .001). Multivariate 
analysis revealed that the patient’s BMI and the type of stress test were statistically 
significant factors for determining the correct radiopharmaceutical dose (P < .001 for 
both).  
Conclusions. For clinical use of the CZT SPECT system, the optimal individual 
  
thallium-201 doses can be determined based on the patient’s BMI and type of stress test. 
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Myocardial perfusion imaging (MPI) with single-photon emission computed 
tomography (SPECT) is widely used for assessing ischemia, viability, and scarring in 
the left ventricular (LV) myocardium.1-4 Although thallium-201-chloride (thallium-201) 
has been used widely, it is considered suboptimal because of its low emission energy 
level (69−80 keV) and its long physical half-life of 73 hours. To circumvent the 
limitations of thallium-201, technetium-99m derivatives have been proposed as 
alternative perfusion tracers.5-7 The higher emission energy of technetium-99m (140 
keV) is better suited for conventional Anger gamma camera imaging, and the shorter 
half-life (6 hours) of this agent allows larger injectable doses, thereby improving image 
quality.3  
Thallium-201, however, is a clinically important radiopharmaceutical for assessing 
both regional blood flow and myocardial viability. Redistribution images have been 
used as important markers of regional viability.8,9 A high-quality redistribution image is 
key to an accurate diagnosis.7,10 With MPI SPECT using a conventional Anger gamma 
camera, at least 100 counts in the hottest pixel of the left ventricle in the left anterior 
oblique 45 projection (acquisition time is 40−60 sec/step) are needed to ensure a 
diagnostic-quality image.11,12 Therefore, the total acquisition time must be within 15−20 
  
minutes. 
Recently, dedicated cardiac systems with cadmium-zinc-telluride (CZT) detectors 
were introduced in Japan. This system uses stationary semiconductor technology. A 
nine-detector column is fixed in a mechanical mounting, no gantry rotation is necessary, 
and data acquisition is performed by rotating these columns in synchrony.11 The 
improvements in efficiency and resolution allow low-dose imaging protocols and reduce 
the acquisition time.13-15 However, the optimal dose of thallium-201 using the CZT 
detectors has not been determined. We aimed to determine the optimal thallium-201 
dose using a new CZT cardiac scanner camera (D-SPECT). 
 
MATERIALS AND METHODS 
Myocardial Phantom Study 
A myocardial phantom (model RH-2®; Kyoto-Kagaku, Kyoto, Japan) was 
developed in which we created a 10-mm defect in the anterior wall and a 20-mm defect 
in the inferior wall. The myocardium portion was filled with thallium-201 (28.5 
kBq/mL). The mediastinum, left ventricle (LV), and right ventricle of the myocardial 
phantom were filled with water. A Teflon rod simulated the spine, and sawdust 
simulated the lungs (Figures 1 and 2). We obtained a total of 0.4–2.0 million counts. We 
  
then assessed the image quality for each myocardial count, scoring it on a three-point 
scale (0, poor; 1, fair; 2, good) and examined the image uniformity, resolution, and 
contrast (e.g., myocardial endocardial and epicardial border definition) and the 
target/background ratio. Two experienced nuclear cardiologists and four radiology 
technologists individually performed the visual scoring. Average scores were calculated 
using quantitative analysis. We then compared them using a circumferential count 
profile curve with Prominence Processor Version 3.1® software (Conference for 
Nuclear Medicine Image Processing, Japan). Circumferential count profile curves are 
used for normalized maximum counts. 
 
Patient Study 
Population. The study population comprised 292 consecutive patients with 
suspected or known coronary artery disease who underwent stress/redistribution testing 
between March and July 2015 using a single injection of thallium-201 to assess 
myocardial viability. The Ethics Committee of Hyogo Brain and Heart Center at Himeji 
(Himeji, Japan) approved this retrospective study. 
Imaging protocol. The imaging protocol is shown in Figure 3. In all, 85 patients 
(29.1%; 65 men, 20 women) with a body mass index (BMI) range of 15.0−30.0 kg/m2) 
  
underwent exercise stress in an upright position on a bicycle ergometer until one of the 
following endpoints was reached: ≥ 85% of predicted maximum heart rate (220 − age in 
years), physical exhaustion, leg fatigue, angina pectoris, ST depression > 2 mm, and 
sustained ventricular tachyarrhythmia. Thallium-201 was injected at peak exercise, and 
the patient was asked to continue at the same pace for an additional minute (1 min).  
In addition, 207 patients (70.9%; 133 men, 74 women) were subjected to 
pharmacological stress that was achieved with adenosine 0.12 mg/kg/min (Adenoscan®; 
Astellas Pharma, Tokyo, Japan) administered for 6 minutes using an intravenous 
infusion pump. After 3 minutes of the infusion, thallium-201 [3−4 mCi (111−148 MBq)] 
was injected intravenously. Stress SPECT imaging was performed 5−10 minutes after 




The CZT SPECT (D-SPECT®; Spectrum Dynamics, Caesarea, Israel) uses nine 
pixilated solid-state CZT crystal detector columns, wide-angle tungsten collimators, and 
region of interest (ROI)-centric scanning. Each column consists of 1024 (16 × 64) 5 mm 
thick CZT elements (2.46 × 2.46 mm). The detectors, rotating in synchrony while 
  
focusing on the ROI (the heart), produce the needed data.13 Imaging was conducted with 
the patient upright in all cases. After 10-sec pre-scan acquisition and positioning the 
heart in the field of view according to previous reports,16 1.5 million LV myocardial 
counts were acquired for both post-stress and redistribution images, with an energy peak 
and energy window width of 71 keV ± 15%. We used an acquisition protocol based on 
total myocardial counts. The imaging myocardial volumetric ROI counts were of high 
order to obtain more than 1.2 million LV myocardial counts. The cardiac cycle was 
divided into 16 equally spaced intervals. Summed and gated projections were 
reconstructed with an iterative maximum likelihood expectation maximization 
algorithm (using a variant of the ordered-subset expectation maximization algorithm) 
using three and four iterations, respectively, and 32 subsets.17 
We calculated an optimal thallium-201 dose that resulted in acceptable LV 
myocardial counts according to a patient-specific classification using redistribution 
images. We also examined the factors that influenced obtaining the optimal dose of 
thallium-201 and found three compounds that were commercially available: 2, 3, and 4 





Statistical analysis was performed with commercial software (StatView version 
5.0® and JMP version 11.2.0®; SAS Institute, Inc., Cary, NC, USA). All continuous 
variables are expressed as means ± SD. Multiple regression analysis was used to 
investigate the possible influence of patient-specific factors regarding their relation with 
the radiopharmaceutical doses. Multivariate analysis was used to determine the 
predictive value of statistically significant patient-specific factors. The results are shown 
as linear regression plots. The decision coefficients were calculated. A value of P < .05 
was considered to indicate statistical significance. 
 
RESULTS 
In the phantom study, we examined the minimum dose for appropriate imaging 
(Table 1). The lowest myocardial count for good-quality imaging detection was 1.2 
million counts for the anterior wall (≤10 mm defect size) (Figure 4). We then calculated 
an optimal dose of thallium-201 that would result in 1.2 million myocardial counts 
during 6 minutes of acquisition time. 
The patient’s clinical characteristics are shown in Table 2. There were 292 
consecutive patients [198 men (67.8%)] with a mean age ± SD of 72.4 ± 9.3 years. A 
  
total of 109 (37.3%) patients had known coronary artery disease. The optimal 
radiopharmaceutical doses were calculated as the ratio of acquisition time 
(minutes)/myocardial counts (millions) based on the injected dose (mCi). It was then 
converted to the dose required for 1.20 million counts for 6 minutes of acquisition time. 
The calculating formula is as follows:  
Optimal radiopharmaceutical dose (mCi)  
= injected dose × (acquisition time/myocardial count)  
× [1.2 (million)/6 (minutes)]                                     (1) 
The multiple regression analysis showed a positive correlation with age (r2 = 0.10, 
P < .001), sex (r2 = 0.02, P = .012), BMI (r2 = 0.25, P < .001), and type of stress test (r2 
= 0.40, P < .001). The multivariate analysis showed that the patient’s BMI (P < .001) 
and the type of stress test (P < .001) contributed to the estimation of injected 
radiopharmaceutical doses. The patient’s age and sex were not statistically significant 
factors (P = .440 and P = .113, respectively). Based on these findings, we could predict 
the optimal radiopharmaceutical doses as follows. 
For the exercise stress test, the optimal radiopharmaceutical doses (mCi) were 
calculated as 
6.85 × BMI – 16.27 (r2 = 0.28, P < .001).                     (2) 
  
For the adenosine stress test, optimal radiopharmaceutical doses (mCi) were 
calculated as 
5.09 × BMI – 22.9 (r2 = 0.29, P < .001).                     (3) 
Linear regressions for the calculated radiopharmaceutical doses and the patient’s 
BMI were compared using linear regression plots (Figure 5). According to the patient’s 
BMI and the type of stress test (exercise, adenosine) the optimal doses were as follows 
(Figure 6).  
2 mCi for adenosine with BMI ≤ 19.2 kg/m2  
3 mCi for exercise with BMI ≤ 17.4 kg/m2 and for adenosine with BMI >19.2 but ≤ 26.0 
kg/m2, and 
4 mCi for exercise with BMI < 17.4 but ≤ 24.2 kg/m2 and for adenosine with BMI > 
26.0 but ≤ 32.8 kg/m2. 
Representative cases are shown in Figure 7. 
The estimated extensions of the acquisition times were 8 and 10 minutes for lower 
radiation doses (Figures 8, 9). With the 10-minute acquisition time, for the exercise 
stress test, 2 mCi was administered in 11 patients (12.9 %) and 3 mCi in 74 patients 
(87.1 %). For the adenosine stress test, 2 mCi was administered in 204 patients (98.6 %) 




We calculated an optimal thallium-201 dose for use with CZT SPECT that resulted 
in 1.2 million counts during 6 minutes of acquisition time. The optimal dose was 
calculated according to the patient’s BMI and the type of stress test. For the exercise 
stress test, optimal radiopharmaceutical doses (mCi) were calculated as 6.85 × BMI – 
16.27 (r2 = 0.28, P < .001). For the adenosine stress test, the optimal 
radiopharmaceutical doses (mCi) were calculated as 5.09 × BMI – 22.9 (r2 = 0.29, P 
< .001).         
MPI is a well-established noninvasive method for identifying regional 
abnormalities in coronary artery blood flow and determining their physiological 
relevance to myocardial function and viability.18 Thallium-201 has been in use since 
approximately 1980 and was responsible for much clinical evidence that accumulated 
during the decade that followed. Technetium 99m-labeled sestamibi, however, was 
approved in 1990.19-21 Despite the fact that technetium-99m offers superior image 
quality (because of lower scatter) and a lower radiation count per unit of injected 
dose,6,19-21 thallium-201 (compared with technetium-99m tracers) has a longer half-life 
and requires a lower injection dose. It is provided in a radiolabeled syringe (fixed at 2, 
  
3, or 4 mCi). Therefore, it is rather difficult to modify the injected dose of thallium-201. 
However, thallium-201 still has many advantages. It is administered as a single injection 
for imaging during a stress/rest MPI protocol, and it provides higher first-pass 
myocardial extraction and lower extra-cardiac activity.7,18 
CZT image quality with thallium-201 was reported to be superior to that achieved 
with the conventional Anger gamma camera,15 and its diagnostic accuracy was not 
inferior to that of conventional SPECT. In a preliminary study, we produced data 
showing that thallium-201 MPI SPECT image quality provided by the CZT system had 
better-quality images than those found with technetium-99m because of the lower extra-
cardiac activity.7,18  
Technetium-99m used with a CZT gamma camera may allow LV myocardial 
counts as low as one million for stress MPI while maintaining excellent agreement 
regarding quantitative perfusion and functional parameters with those determined from 
higher counts.22 In our phantom study, the lowest thallium-201 dose to obtain an 
appropriate image was 1.2 million counts based on the image quality and 
circumferential count profile curve. We then determined the thallium-201 dose needed 
to accumulate 1.2 million LV myocardial counts.  
Our results indicated that different types of stress test (exercise versus adenosine in 
  
this study) require different radiopharmaceutical doses for imaging. Coronary blood 
flow during a pharmacological stress test study was reported to be lower with 
dobutamine or exercise than with adenosine or dipyridamole.23 Our study showed major 
differences in count rates between exercise- and adenosine-induced stress (Figure 5). 
The myocardial perfusion count rate was higher for the adenosine stress test than for the 
exercise stress test 23, 24 in regard to both stress and redistribution, allowing us to reduce 
the injection dose. Other studies have shown that there are sex-related differences 
regarding the myocardial blood flow and the injected pharmaceutical radiation dose,25,26 
whereas we found no statistically significant correlation.  
Reducing the injection radiation dose is important. The most commonly used 
procedure involves administering 3 mCi of thallium-201 (the maximum administered 
dose was 4 mCi). Almost all patients with a 10-minute acquisition time who undergo the 
adenosine stress test have a 33% decreased radiation dose (2 mCi vs. 3 mCi). 
These results suggest that the optimal dose could be lowered depending on the 
patient’s BMI. However, this study was based on a Japanese population using a D-
SPECT camera. Another population and another CZT camera system (Discovery NM 
530c camera; GE Healthcare) could produce somewhat different results. 
 
  
NEW KNOWLEDGE GAINED 
The optimal dose of thallium-201 for MPI SPECT using CZT detectors has not 
been determined. Our results suggest how to determine an optimal dose of thallium-201 
that could contribute to reducing the radiation dose. 
 
CONCLUSIONS 
We determined the optimal dose of thallium-201 for MPI SPECT using a dedicated 
cardiac system with CZT detectors. We suggest tailoring the dose according to the 
patient’s BMI and the method of stress testing, with a lower dose needed for 
pharmacologically induced stress. 
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Figure 1. Photograph shows the configuration of the myocardial phantom. (A) Front 
view. (B) Top view.  
 
Figure 2. Median short-axis and vertical long-axis slice images of a myocardial 
phantom. A 10-mm defect is set in the anterior wall and 20-mm defect in the inferior 
wall. 
 
Figure 3. Study protocol for stress/redistribution myocardial perfusion imaging with 
thallium-201. 
 
Figure 4. Circumferential count profile curve analysis of the myocardial phantom. The 
lowest myocardial counts for quality-approved imaging detection were 1.2 million 
counts for the anterior wall (≤10 mm defect size). 
 
Figure 5. Linear regression plots for radiopharmaceutical doses and body mass index 
(BMI) [1.2 million left ventricular (LV) counts during 6 minutes of acquisition time]. 
Differences in the stress test types: (A) Exercise. (B) Adenosine. 
  
 
Figure 6. Bar graph of the BMI classifies the three dose groups (2, 3, and 4 mCi) 
compared with the types of stress test. It shows the radiopharmaceutical doses needed to 
acquire 1.2 million LV counts during 6 minutes of acquisition time. 
 
Figure 7. Mildly abnormal myocardial perfusion (high-BMI patients) under two 
conditions (top: stress; bottom: redistribution). (A) A 68-year-old man with BMI 26.6 
kg/m2. The stress test was exercise, during which a dose of 3 mCi was injected. 
Redistribution imaging shows 1.3 million myocardial counts during 9.6 minutes of 
acquisition time. (B) A 78-year-old man with BMI 28.8 kg/m2. The stress test was 
adenosine, and the injected dose was 3 mCi. Redistribution imaging show 1.3 million 
myocardial counts during 8.2 minutes of acquisition time. 
 
Figure 8. Linear regression plots for radiopharmaceutical doses and various body mass 
indexes (BMIs) [1.2 million left ventricular (LV) counts during 8 minutes and 10 
minutes of acquisition time]. (A) Exercise stress test (8 minutes of acquisition time). (B) 
Adenosine stress test (8 minutes of acquisition time). (C) Exercise stress test (10 
minutes of acquisition time). (D) Adenosine stress test (10 minutes of acquisition time). 
  
 
Figure 9. Bar graph of the BMI classifies the three dose groups (2, 3, and 4 mCi) 
compared with the types of stress test. It shows the radiopharmaceutical doses needed to 





























































Table 1. Image quality in the myocardial phantom study image quality 
image quality 
Myocardial counts (millions) Average score 
0.4 0.0 ± 0.0 
0.6 0.0 ± 0.0 
0.8 0.0 ± 0.0 
0.9 0.2 ± 0.4 
1.0 
 
0.5 ± 0.5 
1.1 0.8 ± 0.4 
1.2 1.0 ± 0.0 
1.3 1.0 ± 0.0 
1.4 1.0 ± 0.0 
1.5 2.0 ± 0.0 
1.6 2.0 ± 0.0 
1.8 2.0 ± 0.0 
2.0 2.0 ± 0.0 
Data are given as means ± SD 
 
 





Table 2. Patients’ characteristics 
Characteristic Value 
Age (years) 72.4 ± 9.3 









LV stress counts (millions) 1.7 ± 0.3 (range 1.0–2.7) 
LV redistribution counts (millions) 1.7 ± 0.3 (range 1.1–2.7) 
Stress acquisition times (minutes) 4.2± 1.4 (range 2.0–8.3) 
Redistribution acquisition times 
(minutes) 
7.2 ± 2.4 (range 2.6–15.2) 
Prior myocardial infarction  57 (19.5) 
Prior revascularization  67 (23.0) 
Co-morbidities  
 Diabetes  102 (34.9) 
 Hypertension  195 (66.8) 
 Hypercholesterolemia  131 (44.9) 
 Chronic kidney disease 110 (37.2) 
  Smoking  87 (29.8) 
Data are given as mean ± SD or the number (%) 
 
 
BMI: body mass index; LV: left ventricular 
 
BMI, body mass index; LV, left ventricular 
